Sugino, F.; Nakane, K.; Kawase, M.; Ueda, S.; Tomioka, M.; Takeuchi, Y.; Tomioka-Inagawa, R.; Yamada, T.; Namiki, S.; Kumada, N.;
et al. Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life 2023, 13, 1072.
https://doi.org/10.3390/life13051072
AMA Style
Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y, Tomioka-Inagawa R, Yamada T, Namiki S, Kumada N,
et al. Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life. 2023; 13(5):1072.
https://doi.org/10.3390/life13051072
Chicago/Turabian Style
Sugino, Fumiya, Keita Nakane, Makoto Kawase, Shota Ueda, Masayuki Tomioka, Yasumichi Takeuchi, Risa Tomioka-Inagawa, Toyohiro Yamada, Sanae Namiki, Naotaka Kumada,
and et al. 2023. "Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer" Life 13, no. 5: 1072.
https://doi.org/10.3390/life13051072
APA Style
Sugino, F., Nakane, K., Kawase, M., Ueda, S., Tomioka, M., Takeuchi, Y., Tomioka-Inagawa, R., Yamada, T., Namiki, S., Kumada, N., Takeuchi, S., Kawase, K., Kato, D., Takai, M., Iinuma, K., Tobisawa, Y., & Koie, T.
(2023). Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life, 13(5), 1072.
https://doi.org/10.3390/life13051072
